Chemotherapy

Gemcitabine and treosulfan used to treat patients with metastatic uveal melanoma

Published in Cancer Weekly, December 13th, 2005

Gemcitabine and treosulfan were used to treat patients with metastatic uveal melanoma.

According to recent research from Germany, "In-vitro synergy of treosulfan and gemcitabine has been observed in chemotherapy-resistant tumors. This trial investigated the efficacy of gemcitabine plus treosulfan in metastatic uveal melanoma."

"Patients received 1000 mg/m² of gemcitabine and treosulfan at a dose of 2500 or 3000 mg/m² in cohort 1 and 3500 or 4000 mg/m² in cohort 2. Chemotherapy was administered on days 1 and 8 every 4 weeks. Thirty-three patients were treated, 14 in cohort 1 and 19 in cohort 2," explained A. Schmittel...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-12-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry